Healthcare Economist April 2, 2024
The Digital Therapeutics Alliance defines a digital therapeutic (DTx) as “evidence-based therapeutic interventions that are driven by high-quality software programs to prevent, manage, or treat a medical disorder or disease.” One key question is what factors do US payers take into account when evaluating DTx and how does that differ from standard pharmaceuticals. A paper by Gomez Lumbreras et al. (2024) held virtual focus groups with 21 US payers to find the answer. Key considerations include:
- Need for Evidence. Almost all survey respondents (n = 19/21 90%) indicated they would require a clinical trial to consider coverage of the product. This evidence includes data on efficacy, effectiveness and value (including cost-effectiveness perspective)
- DTx Coverage: Medical, Pharmacy or Other? Many...